Stock listing
NASDAQ:NKTX Nkarta, Inc. Stock
Home listing (NASDAQ) of Nkarta, Inc.
Follow Nkarta, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:NKTX
$1.14 USD -0.01 (-1.3%)
Close on Nov 20, 2026
- Day range
- $1.11 – $1.22 USDNov 20, 2026
- Volume
- 1.60M sharesNov 20, 2026
- Market cap
- $81.38M USDAt the close on Nov 20, 2026 · price × 71.70M shares outstanding
- 52-week range
- $1.11 – $3.72 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.01M USDMedian day 781,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NKTX · Home | $1.135 USD | -0.015 (-1.3%) | 1,603,335 | $1.12 | $1.215 | $1.11 | $1.15 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NKTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.135 | -0.015 | -1.3% | $1.12 | $1.215 | $1.11 | 1,603,335 | |
| $1.15 | -0.10 | -8.0% | $1.25 | $1.279 | $1.15 | 811,000 | |
| $1.25 | +0.04 | +3.3% | $1.22 | $1.28 | $1.15 | 1,043,829 | |
| $1.21 | +0.02 | +1.7% | $1.20 | $1.28 | $1.195 | 969,280 | |
| $1.19 | -0.075 | -5.9% | $1.28 | $1.306 | $1.105 | 1,406,689 | |
| $1.265 | -0.215 | -14.5% | $1.43 | $1.43 | $1.26 | 1,021,965 | |
| $1.48 | +0.13 | +9.6% | $1.41 | $1.51 | $1.32 | 1,153,285 | |
| $1.35 | -0.24 | -15.1% | $1.53 | $1.54 | $1.30 | 1,213,659 | |
| $1.59 | -0.14 | -8.1% | $1.40 | $1.60 | $1.13 | 9,298,669 | |
| $1.73 | +0.16 | +10.2% | $1.61 | $1.84 | $1.61 | 1,973,284 | |
| $1.57 | -0.16 | -9.2% | $1.70 | $1.72 | $1.565 | 1,115,697 | |
| $1.73 | +0.20 | +13.1% | $1.58 | $1.745 | $1.56 | 1,842,404 | |
| $1.53 | +0.01 | +0.7% | $1.54 | $1.595 | $1.52 | 726,314 | |
| $1.52 | -0.04 | -2.6% | $1.61 | $1.63 | $1.48 | 1,394,351 | |
| $1.56 | -0.10 | -6.0% | $1.66 | $1.66 | $1.54 | 1,211,807 | |
| $1.66 | -0.06 | -3.5% | $1.74 | $1.76 | $1.65 | 804,985 | |
| $1.72 | +0.02 | +1.2% | $1.67 | $1.73 | $1.63 | 1,049,513 | |
| $1.70 | -0.13 | -7.1% | $1.79 | $1.80 | $1.58 | 2,523,106 | |
| $1.83 | +0.04 | +2.2% | $1.81 | $1.875 | $1.745 | 1,152,068 | |
| $1.79 | +0.05 | +2.9% | $1.74 | $1.81 | $1.66 | 959,200 | |
| $1.74 | -0.01 | -0.6% | $1.75 | $1.81 | $1.72 | 1,679,800 | |
| $1.75 | +0.01 | +0.6% | $1.76 | $1.819 | $1.74 | 1,087,400 | |
| $1.74 | -0.01 | -0.6% | $1.76 | $1.82 | $1.74 | 1,143,700 | |
| $1.75 | -0.05 | -2.8% | $1.84 | $1.85 | $1.75 | 1,436,700 | |
| $1.80 | -0.13 | -6.7% | $1.93 | $1.94 | $1.78 | 1,754,600 | |
| $1.93 | -0.10 | -4.9% | $2.05 | $2.07 | $1.91 | 1,476,800 | |
| $2.03 | -0.07 | -3.3% | $2.08 | $2.11 | $2.02 | 702,300 | |
| $2.10 | -0.07 | -3.2% | $2.15 | $2.18 | $2.05 | 790,600 | |
| $2.17 | -0.08 | -3.6% | $2.25 | $2.275 | $2.14 | 598,400 | |
| $2.25 | +0.03 | +1.4% | $2.23 | $2.307 | $2.14 | 904,900 | |
| $2.22 | -0.05 | -2.2% | $2.25 | $2.26 | $2.16 | 720,200 | |
| $2.27 | -0.04 | -1.7% | $2.26 | $2.335 | $2.25 | 566,500 | |
| $2.31 | -0.22 | -8.7% | $2.55 | $2.55 | $2.295 | 754,600 | |
| $2.53 | -0.045 | -1.7% | $2.57 | $2.57 | $2.45 | 522,100 | |
| $2.575 | +0.015 | +0.6% | $2.60 | $2.625 | $2.52 | 366,800 | |
| $2.56 | -0.06 | -2.3% | $2.59 | $2.67 | $2.545 | 402,300 | |
| $2.62 | 0.00 | 0.0% | $2.65 | $2.69 | $2.55 | 283,200 | |
| $2.62 | -0.05 | -1.9% | $2.68 | $2.68 | $2.53 | 524,600 | |
| $2.67 | -0.08 | -2.9% | $2.75 | $2.785 | $2.67 | 810,700 | |
| $2.75 | -0.10 | -3.5% | $2.86 | $2.86 | $2.725 | 681,100 | |
| $2.85 | +0.09 | +3.3% | $2.72 | $2.89 | $2.585 | 933,800 | |
| $2.76 | -0.19 | -6.4% | $2.91 | $2.99 | $2.615 | 1,091,300 | |
| $2.95 | +0.07 | +2.4% | $2.92 | $2.985 | $2.865 | 415,600 | |
| $2.88 | +0.05 | +1.8% | $2.87 | $2.91 | $2.801 | 385,800 | |
| $2.83 | +0.02 | +0.7% | $2.81 | $2.885 | $2.79 | 609,700 | |
| $2.81 | -0.06 | -2.1% | $2.93 | $2.968 | $2.745 | 531,400 | |
| $2.87 | -0.01 | -0.3% | $2.93 | $3.065 | $2.825 | 642,100 | |
| $2.88 | -0.04 | -1.4% | $2.92 | $2.95 | $2.785 | 458,400 | |
| $2.92 | +0.01 | +0.3% | $2.92 | $3.08 | $2.865 | 491,100 | |
| $2.91 | +0.10 | +3.6% | $2.85 | $3.00 | $2.84 | 486,900 | |
| $2.81 | -0.10 | -3.4% | $2.88 | $2.88 | $2.755 | 559,300 | |
| $2.91 | -0.32 | -9.9% | $3.19 | $3.20 | $2.86 | 781,600 | |
| $3.23 | +0.31 | +10.6% | $2.86 | $3.30 | $2.80 | 1,466,400 | |
| $2.92 | +0.13 | +4.7% | $2.77 | $2.93 | $2.75 | 447,100 | |
| $2.79 | +0.025 | +0.9% | $2.77 | $2.885 | $2.71 | 722,000 | |
| $2.765 | +0.065 | +2.4% | $2.70 | $2.825 | $2.655 | 489,600 | |
| $2.70 | -0.01 | -0.4% | $2.62 | $2.74 | $2.62 | 570,400 | |
| $2.71 | -0.05 | -1.8% | $2.73 | $2.75 | $2.651 | 481,600 | |
| $2.76 | +0.01 | +0.4% | $2.75 | $2.79 | $2.695 | 429,800 | |
| $2.75 | +0.12 | +4.6% | $2.63 | $2.785 | $2.61 | 538,700 | |
| $2.63 | -0.08 | -3.0% | $2.71 | $2.71 | $2.61 | 260,800 | |
| $2.71 | +0.12 | +4.6% | $2.60 | $2.75 | $2.575 | 456,530 | |
| $2.59 | -0.07 | -2.6% | $2.63 | $2.63 | $2.50 | 449,919 | |
| $2.66 | +0.19 | +7.7% | $2.48 | $2.735 | $2.48 | 1,107,100 | |
| $2.47 | -0.07 | -2.8% | $2.53 | $2.54 | $2.395 | 586,800 |
- Ticker
- NASDAQ:NKTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
Latest deck · Nov 9, 2026
ACR Convergence 2026
Conference · 28 slides
Latest news
Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
Nov 11, 2026
Closed $1.48 (+9.6%) on Nov 11, 2026
Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence
Nov 9, 2026
Closed $1.59 (-8.1%) on Nov 9, 2026
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
Nov 6, 2026
Closed $1.59 (-8.1%) on Nov 9, 2026
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 5, 2026
Closed $1.73 (+10.2%) on Nov 6, 2026
Nkarta to Participate in September Investor Conferences
Sep 10, 2026
Closed $2.81 (-3.4%) on Sep 10, 2026
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Sep 8, 2026
Closed $3.23 (+10.6%) on Sep 8, 2026
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
Aug 10, 2026
Closed $2.33 (-5.3%) on Aug 11, 2026
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Jun 26, 2026
Closed $2.83 (+1.8%) on Jun 26, 2026
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
May 12, 2026
Closed $3.06 (-6.7%) on May 13, 2026
Nkarta, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 96 in all · newest Nov 11, 2026 · oldest 2020
- Decks
- 14 decks · latest Nov 9, 2026
Where Nkarta, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NKTX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:NKTX | BOATS | United States | USD |
Valuation
Price/book 0.4× against a median of 2.3×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$75.22M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.67
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Nkarta, Inc. · NASDAQ:NKTX | US$81.38M | −US$75.22M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.67 |
| Shine-On Biomedical Co., Ltd. · TPEX:6926 | US$83.56M | US$59.02M | n/a | 64.8× | n/a | 3.5× | −367.6% | 0.0× | n/a |
| Rallybio Corporation · NASDAQ:RLYB | US$83.29M | −US$7.40M | 3.1× | −17.1× | n/a | 0.9× | n/a | 0.0× | 0.58 |
| TuHURA Biosciences, Inc. · NASDAQ:HURA | US$82.20M | US$89.50M | n/a | n/a | n/a | 4.3× | n/a | 0.5× | 2.81 |
| 3D Medicines, Inc. · HKEX:1244 | US$81.88M | US$48.45M | n/a | 0.9× | n/a | 1.0× | −49.9% | 0.3× | n/a |
| Kintor Pharmaceutical Ltd · HKEX:9939 | US$81.70M | US$96.94M | n/a | 19.8× | n/a | 5.0× | −612.3% | 1.2× | n/a |
| Captor Therapeutics SA · GPW:CTX | US$81.11M | US$64.15M | n/a | 130× | n/a | 5.1× | n/a | 0.0× | n/a |
| Vaxart, Inc. · OTC:VXRT | US$79.89M | US$14.34M | 2.8× | 0.1× | 0.4× | 1.2× | 16.0% | 0.0× | 1.21 |
| Sensorion SAS · EURONEXT:ALSEN | US$79.63M | −US$13.98M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | n/a |
| Adocia SA · EURONEXT:ADOC | US$79.30M | US$77.84M | n/a | 48.1× | n/a | n/a | n/a | n/a | n/a |
| Tiziana Life Sciences Ltd · NASDAQ:TLSA | US$78.98M | US$76.73M | n/a | n/a | n/a | n/a | n/a | n/a | 1.23 |
| Median of the others | US$81.40M | US$61.59M | 2.9× | 19.8× | 0.4× | 2.3× | −208.7% | 0.0× | 1.22 |
Forecasts
6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.80 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.82 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Paul Hastings | CHIEF EXECUTIVE OFFICER |
| Nadir Mahmood | PRESIDENT |
| Shawn Rose | CHIEF MEDICAL OFFICER AND HEAD OF RESEARCH & DEVELOPMENT |
Board
| Director | Role |
|---|---|
| Ali Behbahani | Member of Board of Directors |
| Angela Thedinga | Member of Board of Directors |
| George Vratsanos | Member of Board of Directors |
| Leone Patterson | Member of Board of Directors |
| Mike Dybbs | Director |
| Paul Hastings | CHIEF EXECUTIVE OFFICER |
| Simeon George | Member of Board of Directors |
| Zach Scheiner | Member of Board of Directors |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +10.2% |
| Q2 2026 | Aug 10, 2026 · After close | −5.3% |
| Q1 2026 | May 13, 2026 | −14.3% |
| Q4 2025 | Mar 25, 2026 · After close | +0.5% |
| Q3 2025 | Nov 10, 2025 · After close | +2.5% |
| Q2 2025 | Aug 12, 2025 · After close | +12.8% |
| Q1 2025 | May 14, 2025 · After close | −8.0% |
| Q4 2024 | Mar 19, 2025 · Before open | −0.7% |
| Q3 2024 | Nov 7, 2024 · After close | −2.5% |
| Q2 2024 | Aug 13, 2024 · After close | +3.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −0.8% |
| Q4 2023 | Mar 21, 2024 · After close | −31.3% |
| Q3 2023 | Nov 9, 2023 · After close | −1.0% |
| Q2 2023 | Aug 10, 2023 · Before open | +1.5% |
| Q1 2023 | May 11, 2023 · After close | +0.5% |
| Q4 2022 | Mar 16, 2023 · After close | +2.4% |
| Q3 2022 | Nov 9, 2022 · After close | −2.3% |
| Q2 2022 | Aug 11, 2022 · After close | +11.3% |
| Q1 2022 | May 12, 2022 · After close | +10.6% |
| Q4 2021 | Mar 17, 2022 · After close | +5.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| ACR Convergence 2026 | Conference | 28 slides | Nov 9, 2026 |
| Investor Presentation (May 2026) | Investor deck | 21 slides | May 2026 |
| Investor Presentation (March 2024) | Investor deck | 27 slides | Mar 25, 2024 |
| Investor Presentation (January 2024) | Investor deck | 24 slides | Jan 8, 2024 |
| Technical Presentation (June 2023) | Technical | 19 slides | Jun 27, 2023 |
| EHA 2023 | Conference | 15 slides | Jun 10, 2023 |
| Corporate Update (December 2022) | Corporate update | 19 slides | Dec 5, 2022 |
| Corporate Update (April 2022) | Corporate update | 26 slides | Apr 25, 2022 |
| Investor Presentation (October 2021) | Investor deck | 32 slides | October 2021 |
| Investor Presentation (July 2021) | Investor deck | 33 slides | July 2021 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (June 2021) | Investor deck | 32 slides | June 2021 |
| Investor Presentation (May 2021) | Investor deck | 32 slides | May 2021 |
| Investor Presentation (April 2021) | Investor deck | 30 slides | April 2021 |
| Investor Presentation (November 2020) | Investor deck | 28 slides | November 2020 |
IPO
Priced at US$18.00 a share on Jul 9, 2020.
- Price
- US$18.00 a share
- Shares offered
- 14,000,000 shares of common stock
- Offering size
- US$252 million
- Underwriters
- Cowen, Evercore ISI, Stifel, Mizuho Securities · In the order on the cover
- Shares delivered
- On or about Jul 14, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 28, 2020 |
| Filed publicly | Jun 19, 2020 |
| Amended 3 times | Newest Jul 9, 2020 |
| Shares registered with an exchange | Jul 2, 2020 |
| Declared effective by the SEC | Jul 9, 2020 |
| Final prospectus, with the price | Jul 13, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 13, 2020 |
| S-1MEF · Registration of more shares for the same offering | Jul 10, 2020 |
| EFFECT · Notice that a registration is effective | Jul 9, 2020 |
| S-1/A · Registration statement, amended | Jul 9, 2020 |
| CERT · Exchange's certificate of listing | Jul 9, 2020 |
| S-1/A · Registration statement, amended | Jul 9, 2020 |
| CORRESP · Letter to the SEC | Jul 8, 2020 |
| UPLOAD · Letter from the SEC | Jul 8, 2020 |
| CORRESP · Letter to the SEC | Jul 7, 2020 |
| CORRESP · Letter to the SEC | Jul 7, 2020 |
All 25 filings
| Filing | Filed |
|---|---|
| 8-A12B · Registration of shares for listing on an exchange | Jul 2, 2020 |
| CORRESP · Letter to the SEC | Jul 2, 2020 |
| S-1/A · Registration statement, amended | Jul 2, 2020 |
| UPLOAD · Letter from the SEC | Jul 1, 2020 |
| CORRESP · Letter to the SEC | Jun 29, 2020 |
| CORRESP · Letter to the SEC | Jun 19, 2020 |
| S-1 · Registration statement | Jun 19, 2020 |
| UPLOAD · Letter from the SEC | Jun 1, 2020 |
| DRS/A · Draft registration statement, amended | May 19, 2020 |
| DRSLTR · Letter to the SEC with a draft | May 18, 2020 |
| UPLOAD · Letter from the SEC | Apr 28, 2020 |
| DRS/A · Draft registration statement, amended | Apr 20, 2020 |
| DRSLTR · Letter to the SEC with a draft | Apr 17, 2020 |
| UPLOAD · Letter from the SEC | Mar 23, 2020 |
| DRS · Draft registration statement | Feb 28, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 13, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 115.0K | ||||
| Research and development | 90.4M | 96.7M | 96.8M | 90.9M | 63.4M | 36.2M | 17.2M |
| Operating income | -122.0M | -128.2M | -131.7M | -119.0M | -86.4M | -51.5M | -22.3M |
| Depreciation and amortization | 9.20M | 9.20M | 5.90M | 2.60M | 1.80M | 800.0K | 400.0K |
| EBITDA | -112.8M | -119.0M | -125.8M | -116.4M | -84.6M | -50.7M | -21.9M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -104.1M | -108.8M | -117.5M | -113.8M | -86.1M | -91.4M | -21.1M |
| Earnings per share, basic | -1.41 | -1.60 | -2.40 | -2.61 | -2.62 | -5.44 | -14.41 |
| Earnings per share, diluted | -1.41 | -1.60 | -2.40 | -2.61 | -2.62 | -5.44 | -14.41 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 39.6M | 27.9M | 31.0M | 37.5M | 60.8M | 96.7M | 20.6M |
| Short-term investments | 236.6M | 239.5M | 217.1M | 314.6M | 177.3M | 218.2M | 16.4M |
| Current assets | 282.5M | 273.3M | 253.1M | 360.7M | 245.8M | 318.8M | 37.5M |
| Property, plant and equipment | 66.7M | 74.7M | 79.3M | 61.9M | 12.9M | 9.35M | 3.08M |
| Total assets | 404.2M | 501.2M | 378.9M | 472.9M | 273.9M | 337.6M | 48.4M |
| Accounts payable | 2.09M | 638.0K | 3.67M | 1.76M | 1.11M | 1.18M | 1.88M |
| Current liabilities | 22.3M | 18.9M | 23.3M | 22.0M | 12.9M | 8.83M | 8.16M |
| Total liabilities | 91.9M | 93.2M | 105.6M | 100.7M | 22.9M | 16.4M | 14.1M |
| Shareholders' equity | 312.3M | 408.0M | 273.3M | 372.2M | 251.0M | 321.2M | -25.5M |
| Shares outstanding | 71.1M | 70.6M | 49.2M | 48.9M | 33.0M | 32.6M | 1.60M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -88.7M | -99.7M | -86.2M | -57.0M | -67.9M | -43.5M | -18.4M |
| Capital spending | -1.21M | -4.41M | -28.1M | -47.1M | -5.03M | -7.51M | -1.93M |
| Free cash flow | -89.9M | -104.1M | -114.3M | -104.1M | -73.0M | -51.0M | -20.3M |
| Cash from investing | 100.3M | -129.6M | 79.0M | -184.7M | 32.5M | -210.1M | -18.3M |
| Cash from financing | 141.0K | 226.1M | 691.0K | 219.0M | 1.20M | 329.8M | 49.6M |
| Change in cash | 11.8M | -3.17M | -6.45M | -22.7M | -34.2M | 76.2M | 12.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 19, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 6, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Apr 3, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 1, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 31, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 25, 2026 | Current report | SEC |
| S-3 · Registration statement | Mar 25, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 5, 2026 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 24, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 21, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Mar 26, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 27, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 2, 2025 | Offer document | SEC |
| SC 13G · Big-stake notice | Dec 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 25, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 8-K/A · Current report, amended | Aug 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jul 31, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 16, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 16, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 27, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 15, 2024 | Meeting notice | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 5, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 29, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 28, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 28, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 28, 2024 | Current report | SEC |
| 424B5 · Prospectus | Mar 25, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 25, 2024 | Current report | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 1, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 12, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 31, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jan 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jan 3, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| SC 13G · Big-stake notice | Nov 3, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 27, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 26, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Oct 17, 2023 | Results | SEC |
| 8-K · Current report | Oct 16, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 10, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 23, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 5, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 5, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 27, 2023 | Current report | SEC |
| 8-K · Current report | Jun 26, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | May 10, 2023 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | May 8, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 3, 2023 | Other filings | SEC |
| S-3/A · Registration statement, amended | Apr 24, 2023 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 24, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2023 | Meeting notice | SEC |
This page holds 200 of 440 filings. Open Filings
Cap table
Built by 6ix from Nkarta, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 71,704,404
- Fully diluted
- 71,704,404
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 71,704,404 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 71,704,404 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Feb 14, 2022 |
| Ali Behbahani Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); NeueHealth Inc (Director · Since at least Oct 2, 2025); Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Black Diamond Therapeutics, Inc. (Director · Since at least Jan 29, 2020); Adaptimmune Therapeutics PLC (Director · Since at least Jul 2, 2019); CRISPR Therapeutics AG (Director · Since at least Jun 11, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past) | Director · Since at least Jul 9, 2020 |
| Leone Patterson Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Apr 3, 2025); Zymeworks Inc. (EVP, Chief Bus & Fin Officer · Since at least Sep 1, 2024); Tenaya Therapeutics, Inc. (Chief Fin. and Bus. Officer · Feb 15, 2023 – Feb 23, 2024 · Past); Climb Bio, Inc. (Director · May 19, 2022 – May 19, 2022 · Past) | Director · Since at least Jun 8, 2022 |
| Michael Dybbs Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Kalaris Therapeutics, Inc. (Director · Since at least Mar 18, 2025); Sutro Biopharma, Inc. (Member, Board of Directors · Since at least Sep 26, 2018); Dimension Therapeutics (Director · Oct 21, 2015 – Nov 7, 2017 · Past) | Director · Since at least Jul 9, 2020 |
| Simeon George Other companies: ADARx Pharmaceuticals, Inc. (Director · Since at least Sep 24, 2026); Design Therapeutics, Inc. (Director · Since at least Jun 15, 2022); CRISPR Therapeutics AG (Director · Since at least Jun 9, 2022); Turning Point Therapeutics Inc (Director · Aug 17, 2022 – Aug 17, 2022 · Past) | Director · Since at least Apr 28, 2022 |
| Laura Shawver Other companies: ARS Pharmaceuticals, Inc. (Director · Since at least Dec 3, 2020); Relay Therapeutics, Inc. (Director · Jul 15, 2020 – Jun 3, 2024 · Past); Synthorx Inc (President and CEO, Director · Dec 6, 2018 – Jan 23, 2020 · Past) | Director · Jul 9, 2020 – Jun 8, 2022 · Past |
| Kanya Rajangam Other companies: Senti Biosciences Holdings, Inc. (Pres. & Chief Med. & Dev. Off. · Since at least Jul 5, 2022); Turnstone Biologics Corp. (Director · Jul 20, 2023 – Jun 3, 2024 · Past) | Chief Medical Officer · Jul 9, 2020 – Jan 14, 2022 · Past |
| Paul Hastings Other companies: enGene Therapeutics Inc. (Director · Since at least May 15, 2024); Pacira BioSciences, Inc. (Director · Jun 12, 2024 – Jun 12, 2024 · Past) | Chief Executive Officer, Director · Since at least Jan 4, 2024 |
| Zach Scheiner Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024) | Member of Board of Directors · Since at least Jul 9, 2020 |
| Alicia J Hager Other companies: OncoMed Pharmaceuticals Inc (SVP and General Counsel · Oct 7, 2017 – Apr 23, 2019 · Past) | Chief Legal Officer · Oct 26, 2020 – Jan 15, 2025 · Past |
All 15 people
| Person | Seat |
|---|---|
| Mike Dybbs Other companies: Kalaris Therapeutics, Inc. (Director & Co-founder · Since at least Nov 8, 2024) | Director · Since at least Nov 4, 2026 |
| Angela Thedinga | Member of Board of Directors · Since at least Nov 4, 2026 |
| George Vratsanos | Member of Board of Directors · Since at least Jun 13, 2024 |
| Nadir Mahmood | PRESIDENT · Since at least Jul 29, 2024 |
| Shawn Rose | CHIEF MEDICAL OFFICER AND HEAD OF RESEARCH & DEVELOPMENT · Since at least Jun 6, 2025 |
Log in to ask 6ix AI your own questions about Nkarta, Inc.